NASDAQ:FOLD

Amicus Therapeutics (FOLD) Stock Forecast, Price & News

$12.21

-0.09 (-0.73%)

(As of 09/21/2023 ET)

Compare

Today's Range: $11.91
▼
$12.30
50-Day Range: $12.21
▼
$13.86
52-Week Range: $9.10
▼
$14.10

Volume: 1.63 million shs
Average Volume: 1.85 million shs
Market Capitalization: $3.51 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.20

Amicus Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 24.5% Upside
$15.20 Price Target
Short Interest: Bearish
6.84% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.28
Upright™ Environmental Score
News Sentiment: 0.60
Based on 5 Articles This Week
Insider Trading: Selling Shares
$1.65 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.43) to $0.08 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.68 out of 5 stars

Medical Sector

800th out of 965 stocks

Pharmaceutical Preparations Industry

375th out of 446 stocks

2.3

Analyst's Opinion

Consensus Rating
Amicus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.20, Amicus Therapeutics has a forecasted upside of 24.5% from its current price of $12.21.
Amount of Analyst Coverage
Amicus Therapeutics has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.84% of the outstanding shares of Amicus Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Amicus Therapeutics has a short interest ratio ("days to cover") of 8.5.
Change versus previous month
Short interest in Amicus Therapeutics has recently increased by 3.10%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Amicus Therapeutics does not currently pay a dividend.
Dividend Growth
Amicus Therapeutics does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Amicus Therapeutics has received a 63.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Fabry disease medication", "Clinical research services for genetic diseases", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Amicus Therapeutics is -1.28.

2.6

News and Social Media Coverage

News Sentiment
Amicus Therapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Amicus Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 11 people have searched for FOLD on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.
MarketBeat Follows
4 people have added Amicus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amicus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,654,873.00 in company stock.
Percentage Held by Insiders
Only 2.10% of the stock of Amicus Therapeutics is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Amicus Therapeutics are expected to grow in the coming year, from ($0.43) to $0.08 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amicus Therapeutics is -19.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amicus Therapeutics is -19.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Amicus Therapeutics has a P/B Ratio of 27.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Amicus Therapeutics (NASDAQ:FOLD) Stock

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

FOLD Price History

30 days | 90 days | 365 days | Advanced Chart

FOLD Stock News Headlines

September 20, 2023 | americanbankingnews.com

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of "Moderate Buy" by Analysts

September 1, 2023 | stocknews.com

Which of These 3 Biotech Stocks Are a Buy, Sell, or Hold?

September 22, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

September 1, 2023 | finance.yahoo.com

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023

August 29, 2023 | finance.yahoo.com

Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023

August 25, 2023 | seekingalpha.com

Amicus Therapeutics: U.K. Approval Expands Global Reach

August 21, 2023 | markets.businessinsider.com

Amicus Therapeutics Names Simon Harford New CFO With Immediate Effect

August 16, 2023 | finance.yahoo.com

Amicus Therapeutics Inc (AM6.SG)

September 22, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

August 15, 2023 | finance.yahoo.com

Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom

August 15, 2023 | finance.yahoo.com

Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom

August 9, 2023 | stocknews.com

Moderna (MRNA) vs. Amicus Therapeutics (FOLD): Which Biotech Stock Should You Add to Your Portfolio?

August 9, 2023 | finance.yahoo.com

Amicus (FOLD) Misses on Q2 Earnings, Raises Revenue Guidance

August 8, 2023 | finance.yahoo.com

Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates

August 7, 2023 | seekingalpha.com

Amicus Therapeutics Q2 2023 Earnings Preview

August 7, 2023 | finance.yahoo.com

Why Earnings Season Could Be Great for Amicus Therapeutics (FOLD)

August 4, 2023 | finance.yahoo.com

Zacks.com featured highlights include First Watch Restaurant Group, VersaBank and Amicus Therapeutics

July 31, 2023 | finance.yahoo.com

Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023

July 23, 2023 | finance.yahoo.com

Amicus Therapeutics' (NASDAQ:FOLD) investors will be pleased with their favorable 33% return over the last year

July 17, 2023 | finance.yahoo.com

Amicus Therapeutics Stock Sees Improving Market Leadership; Earns 81 RS Rating

July 14, 2023 | stocknews.com

3 Top Biotech Stocks to Purchase Right Away

July 11, 2023 | msn.com

Morgan Stanley Reiterates Amicus Therapeutics (FOLD) Equal-Weight Recommendation

June 27, 2023 | finanznachrichten.de

Amicus Therapeutics, Inc.: Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union

June 27, 2023 | finance.yahoo.com

Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union

June 5, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Amicus (FOLD), Teladoc (TDOC) and Bristol Myers (BMY)

June 4, 2023 | finance.yahoo.com

Amicus Therapeutics, Inc. (NASDAQ:FOLD): Is Breakeven Near?

May 26, 2023 | seekingalpha.com

FOLD Amicus Therapeutics, Inc.

See More Headlines

Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FOLD Company Calendar

Last Earnings: 8/08/2023
Today: 9/21/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:FOLD
CUSIP: 03152W10
CIK: 1178879
Web: www.amicusrx.com
Phone: (215) 921-7600
Fax: 609-662-2001
Employees: 484
Year Founded: 2002

Price Target and Rating

Average Stock Price Forecast: $15.20
High Stock Price Forecast: $17.00
Low Stock Price Forecast: $11.00
Forecasted Upside/Downside: +24.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-236,570,000.00
Net Margins: -52.85%
Pretax Margin: -55.06%
Return on Equity: -157.79%
Return on Assets: -25.43%

Debt

Debt-to-Equity Ratio: 3.53
Current Ratio: 2.72
Quick Ratio: 2.40

Sales & Book Value

Annual Sales: $329.23 million
Price / Sales: 10.65
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.44 per share
Price / Book: 27.75

Miscellaneous

Outstanding Shares: 287,120,000
Free Float: 281,091,000
Market Cap: $3.51 billion
Optionable: Optionable
Beta: 0.86

Social Links

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. John F. Crowley (Age 56)
Exec. Chairman
Comp: $1.88M

Mr. Bradley L. Campbell M.B.A. (Age 47)
CEO, Pres & Director
Comp: $984.09k

Ms. Ellen S. Rosenberg (Age 60)
Chief Legal Officer & Corp. Sec.
Comp: $733.94k

Mr. David M. Clark (Age 48)
Chief People Officer
Comp: $701.39k

Ms. Daphne E. Quimi CPA (Age 57)
M.B.A., Sr. VP of Fin.
Comp: $748.4k

Dr. Jeffrey P. Castelli (Age 51)
Chief Devel. Officer
Comp: $709.64k

Mr. Simon Nicolas Reade Harford (Age 62)
Chief Financial Officer

Ms. Samantha Prout (Age 45)
Chief Accounting Officer & Controller

Dr. Jill Weimer Ph.D.
Chief Science Officer

Andrew Faughnan
Sr. Director of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FOLD Stock - Frequently Asked Questions

Should I buy or sell Amicus Therapeutics stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FOLD shares.
View FOLD analyst ratings or view top-rated stocks.
What is Amicus Therapeutics' stock price forecast for 2023?: 5 Wall Street research analysts have issued 1-year price objectives for Amicus Therapeutics' shares. Their FOLD share price forecasts range from $11.00 to $17.00. On average, they predict the company's stock price to reach $15.20 in the next twelve months. This suggests a possible upside of 24.5% from the stock's current price.
View analysts price targets for FOLD or view top-rated stocks among Wall Street analysts.
How have FOLD shares performed in 2023?: Amicus Therapeutics' stock was trading at $12.21 at the start of the year. Since then, FOLD stock has increased by 0.0% and is now trading at $12.21.
View the best growth stocks for 2023 here.
When is Amicus Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our FOLD earnings forecast.
How were Amicus Therapeutics' earnings last quarter?: Amicus Therapeutics, Inc. (NASDAQ:FOLD) released its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.03. The biopharmaceutical company had revenue of $94.50 million for the quarter, compared to analyst estimates of $89.57 million. Amicus Therapeutics had a negative trailing twelve-month return on equity of 157.79% and a negative net margin of 52.85%.
What ETFs hold Amicus Therapeutics' stock?: ETFs with the largest weight of Amicus Therapeutics (NASDAQ:FOLD) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), Global X Guru Index ETF (GURU), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), iShares U.S. Pharmaceuticals ETF (IHE) and Principal Healthcare Innovators ETF (BTEC).
What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?: 21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amicus Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).
What is Amicus Therapeutics' stock symbol?: Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."
Who are Amicus Therapeutics' major shareholders?: Amicus Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.34%), JPMorgan Chase & Co. (4.72%), State Street Corp (3.89%), Point72 Asset Management L.P. (2.44%), Geode Capital Management LLC (1.90%) and Fiera Capital Corp (1.75%). Insiders that own company stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Hung Do, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends.
How do I buy shares of Amicus Therapeutics?: Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Amicus Therapeutics' stock price today?: One share of FOLD stock can currently be purchased for approximately $12.21.
How much money does Amicus Therapeutics make?: Amicus Therapeutics (NASDAQ:FOLD) has a market capitalization of $3.51 billion and generates $329.23 million in revenue each year. The biopharmaceutical company earns $-236,570,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis.
How many employees does Amicus Therapeutics have?: The company employs 484 workers across the globe.
How can I contact Amicus Therapeutics?: Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The official website for the company is www.amicusrx.com. The biopharmaceutical company can be reached via phone at (215) 921-7600, via email at afaughnan@amicusrx.com, or via fax at 609-662-2001.

This page (NASDAQ:FOLD) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial